Mobile

A Phase IIa randomised, double-blind, placebo controlled, parallel group, multicentre study evaluating the efficacy, safety, tolerability and pharmacokinetics of AZD1386 after 3 weeks of treatment in...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-012094-35

A Phase IIa randomised, double-blind, placebo controlled, parallel group, multicentre study evaluating the efficacy, safety, tolerability and pharmacokinetics of AZD1386 after 3 weeks of treatment in patients with Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the analgesic efficacy of 21 days of oral administration of AZD1386 compared to placebo in patients with Post Traumatic Neuralgia (PTN) or Post Herpetic Neuralgia (PHN) with mechanical hypersensitivity

Critère d'inclusion

  • Patients with Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN),Intended Indication is Neuropathic Pain

Liens